Clinical Trials

Clinical Trials Currently Recruiting

See below for further details, or contact us at clinicaltrials@syndax.com

Revumenib Clinical Trials

AUGMENT-101

Now Recruiting

A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101).
AUGMENT-102

Now Recruiting

A Study of SNDX-5613 in Combination With Chemotherapy in Participants With Leukemia (AUGMENT-102).

Axatilimab Clinical Trials

AGAVE-201

Now Recruiting

A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy.

To learn more about our clinical trials, please contact us at clinicaltrials@syndax.com.

Syndax is very interested in pursuing innovative explorations in science. If you are interested in collaborating with us, please contact us through collaborate@syndax.com.